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Abstract
Lentiviral envelope (Env) antigenic variation and associated immune evasion present major obstacles to vaccine
development. The concept that Env is a critical determinant for vaccine efficacy is well accepted, however defined correlates
of protection associated with Env variation have yet to be determined. We reported an attenuated equine infectious anemia
virus (EIAV) vaccine study that directly examined the effect of lentiviral Env sequence variation on vaccine efficacy. The
study identified a significant, inverse, linear correlation between vaccine efficacy and increasing divergence of the challenge
virus Env gp90 protein compared to the vaccine virus gp90. The report demonstrated approximately 100% protection of
immunized ponies from disease after challenge by virus with a homologous gp90 (EV0), and roughly 40% protection against
challenge by virus (EV13) with a gp90 13% divergent from the vaccine strain. In the current study we examine whether the
protection observed when challenging with the EV0 strain could be conferred to animals via chimeric challenge viruses
between the EV0 and EV13 strains, allowing for mapping of protection to specific Env sequences. Viruses containing the
EV13 proviral backbone and selected domains of the EV0 gp90 were constructed and in vitro and in vivo infectivity
examined. Vaccine efficacy studies indicated that homology between the vaccine strain gp90 and the N-terminus of the
challenge strain gp90 was capable of inducing immunity that resulted in significantly lower levels of post-challenge virus
and significantly delayed the onset of disease. However, a homologous N-terminal region alone inserted in the EV13
backbone could not impart the 100% protection observed with the EV0 strain. Data presented here denote the complicated
and potentially contradictory relationship between in vitro virulence and in vivo pathogenicity. The study highlights the
importance of structural conformation for immunogens and emphasizes the need for antibody binding, not neutralizing,
assays that correlate with vaccine protection.
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Introduction
The science of preventing infectious diseases is an advancing,
ever-evolving discipline re-invigorated continuously by the chal-
lenge to overcome persistent infections as well as the emergence of
new acute epidemics. While the field of vaccinology has developed
new, cutting-edge techniques, utilizing very traditional approaches
to vaccine development can still demonstrate important lessons.
One such vaccine model is the live-attenuated (attenuated)
vaccine. Attenuated virus vaccines are under evaluation for a
variety of emerging viral maladies while also currently used for the
prevention of infectious diseases such as influenza, chicken pox,
and yellow fever, and have effectively controlled substantial viral
outbreaks such as smallpox, polio, and measles epidemics [1–3].
However, the use of an attenuated human immunodeficiency virus
(HIV) vaccine has been controversial due to obvious concerns
surrounding vaccine safety [4–12]. Regardless of the low potential
for public or commercial use of an attenuated vaccine for HIV, the
attenuated model itself is, to date, one of the best measures of both
potential vaccine efficacy and correlates of protection, and remains
an asset to the field of study.
The development of vaccines to HIV-1 has relied substantially
on the use of animal lentivirus models to evaluate the efficacy of
various vaccine strategies. EIAV, a macrophage-tropic lentivirus,
produces a persistent infection in horses and a chronic dissemi-
nated disease of worldwide importance in veterinary medicine
(reviewed in Craigo and Montelaro, 2008 and Montelaro, Ball,
et al. 1993). The virus infection, transmitted via blood-feeding
insects or iatrogenic sources (i.e. contaminated syringe needles),
occurs in three stages: acute, chronic, and inapparent. EIA is
characterized during its acute and chronic stages by well-defined
episodes of clinical disease triggered by waves of viremia and
distinguished by fever, anemia, thrombocytopenia, edema, and
various wasting signs. By 8–12 months post-infection horses
typically progress to life-long inapparent carriers, but maintain
varying steady state levels of viral replication in monocyte-rich
tissue reservoirs [13–16]. Stress or immune suppression of EIAV
inapparent carriers can induce an increase in viral replication and
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potentially a recrudescence of disease [17–19]. Among virulent
lentiviruses, however, EIAV is unique in that despite aggressive
virus replication and associated rapid antigenic variation, greater
than 90% of infected animals progress from a chronic disease state
to an inapparent carrier stage. This progression to an inapparent
stage of disease is achieved by a strict immunologic control over
virus replication [13,16]. The EIAV system therefore serves as a
uniquely dynamic model for the natural immunologic control of
lentiviral replication and disease. Thus, the EIAV model provides
a novel and useful lentiviral system for identifying immune
correlates of protection and ascertaining the potential for
developing effective prophylactic lentivirus vaccines.
Over the past 20 years we have evaluated a number of
experimental EIAV vaccines [20–28]. Results of these vaccine
trials demonstrate a noteworthy breadth of efficacy, ranging from
protection from detectable infection and/or disease to severe
enhancement of EIAV replication and disease. The most recent of
this vaccine work has been an ongoing series of studies focusing on
an attenuated EIAV proviral vaccine containing a non-functional
viral S2 accessory gene (EIAVD9) [24–27]. Results of the initial
studies confirmed that the EIAV system mirrors other animal
lentivirus vaccine models that have consistently identified atten-
uated vaccines, as producing the highest level of vaccine
protection, typically against homologous virus challenge where
EIAVD9 confers 100% protection [24–27,29–32].
Recent published reports of this attenuated EIAV vaccine
system detail the specific effects of Env sequence variation on
vaccine protection and associated correlations with protection
[27,28,33,34]. We identified for the first time a significant, inverse,
linear correlation between vaccine efficacy and increasing
divergence of the challenge virus Env surface gp90 protein
compared to the vaccine virus gp90 protein. The vaccine study
demonstrated approximately 100% protection of immunized
horses from disease after challenge by virus with a homologous
gp90 (EV0), but less than 50% protection against challenge by
virus with a gp90 that was 13% (EV13) divergent from the vaccine
strain. Immune analysis of potential correlates of protection
between the three challenge groups revealed minor associations,
but were not definitive. Most recently we demonstrated that the
attenuated vaccine strain progressively evolved during the six-
month pre-challenge period and that the observed protection from
disease was significantly associated with divergence from the
original vaccine strain, not the overall diversity present on the day
of challenge (DOC) [28].
Attempts to map immune protection to specific domains of the
Env gp90 gene [27] through analysis of humoral and cellular
immune responses failed to identify an immune correlate of
protection with any level of statistical significance. Here we
describe a study to evaluate directly the effect of variant Env gp90
domains on vaccine efficacy in a very controlled and detailed
manner by developing new challenge strains with chimeric gp90
sequences. The constructed chimeric proviral EIAV challenge
viruses were based on the Env gp90 sequences from the two
extremes of EIAVD9 vaccine protective efficacy from the 2007,
2010 studies: 100% protection (EV0) vs 40% protection (EV13)
[27,28]. The N-terminus and C-terminus of the EV0 and EV13
were exchanged and two chimeric proviral strains evaluated for
pathogenesis and against vaccine protection induced by the
EIAVD9 attenuated vaccine. Results from both the virulence
study and EIAVD9 vaccine trial indicate that recombinant
chimeric virus strains have a complex nature in vitro and in vivo.
Results
Construction and in vitro Testing of Chimeric Proviral
EIAV Strains
To examine regional-specific genomic affects of the Env gp90
on viral virulence and vaccine efficacy, two chimeric Env gp90
EIAV strains were constructed. Virulent challenge strains from a
previous EIAV vaccine study on the affects of Env variation on
vaccine efficacy [27,28] were utilized as parental strains. The two
strains, termed EV0 and EV13, were virulent challenge strains
that were 13% divergent from each other in their particular gp90
envelope sequences and 0% or 13% divergent, respectively, from
the attenuated vaccine strain gp90. Hence, the gp90 sequence of
EV0 was homologous to that of the attenuated EIAVD9 vaccine
strain and animals vaccinated with EIAVD9 were protected against
challenge with EV0 unlike the animals challenged with EV13
where protection from EIA disease was reduced to approximately
40%. The goal of the chimeric constructs was to confer the vaccine
protection phenotype of the EV0 strain into the EV13 backbone
by means of the N-terminal or C-terminal (or both) regions of the
surface protein. To construct these chimeric strains, the gp90
regions of EV0 and EV13 were both split in the highly conserved
genomic region between the fourth and fifth variable domains of
the gene (Figure 1A). The corresponding N-terminus and C-
terminus of the reciprocal gp90 genes were cloned into the
genome of the respective proviral backbones. The resultant
chimeric strains, termed EVNTerm and EVCTerm, were sequenced
to verify the integrity of the viral genome. Viral stocks were
generated and tittered. Viral replication kinetics of the two
chimeric strains were compared to that of the parental strains by
infection of fetal equine kidney (FEK) cells (Figure 1B). Reverse
transcriptase activity of the infected-cell supernatants indicated
that in vitro replication of the two chimeric proviral strains was
almost identical to that of their parental stains.
In vivo Virulence and Pathogenesis of Chimeric Proviral
EIAV Strains, EVNTerm and EVCTerm
The virulence of the chimeric EIAV strains EVNTerm and
EVCTerm, and their ability to cause disease in equids, was
evaluated utilizing our standard in vivo infection model of EIAV
infection and disease [14,18,19,22,24–27,35–46]. Two groups
consisting of four EIAV-naı¨ve ponies were inoculated I.V. with
103 TCID50 of either EVNTerm or EVCTerm. Inoculated ponies
were monitored daily for clinical signs of EIA (fever, lethargy,
petechiation, diarrhea), and blood samples were taken at regular
intervals for measurement of platelets and plasma virus levels
(Figure 2). Three of the four EVNTerm ponies rapidly developed
acute EIA by three weeks post-infection (Figure 2A–D, Figure 3).
Increased temperatures accompanied by drops in platelets, the
hallmark of EIA, were observed in all three subjects. Evaluation of
plasma viral loads determined that the ponies averaged approx-
imately 105 copies RNA/ml plasma during the infection, and that
the febrile episode viremia levels were between 106 and 107 copies
RNA/ml plasma. Pony #D47 had three disease episodes during
chronic disease and had to be euthanized (Figure 2C). The fourth
EVNTerm pony, #G34, had approximately 10-fold lower level of
steady state viral RNA and never developed the signs of clinical
disease (Figure 2D). Only a single pony from the EVCTerm group
developed the clinical signs of EIA (Figure 2E–H, Figure 3). Pony
#G33 had plasma viral levels similar to the EVNTerm-infected
ponies, and experienced clinical EIA accompanied by 105 copies/
ml plasma RNA within the first 3 weeks post-infection. The
remaining 3 ponies of the EVCTerm group, however, did not
experience any clinical symptoms throughout the 90-day obser-
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vation period (Figure 2E–G, Figure 3). The viral loads of these
three animals were also approximately 10-fold lower than their
afebrile EVNTerm counterparts, demonstrating fairly steady repli-
cation at 103 copies RNA/ml plasma. At the close of the
pathogenicity study, 25% of EVNTerm-infected ponies lacked
clinical signs of disease, while 75% of EVCTerm-infected ponies did
not develop clinical EIA disease (Figure 3). The low level of
virulence observed with the EVCTerm strain made it unsuitable as a
pathogenic challenge virus, and hence was not utilized as part of
the trial designed to assess protection from disease.
Clinical, Virological, and Immunological Response to
Experimental EIAVD9 Vaccination
To examine whether protection could be conferred to the EV13
challenge strain by replacing the EV13 gp90 N-terminus with the
gp90 N-terminus of the EV0 strain, five EIAV-naı¨ve ponies were
vaccinated with our EIAVD9 attenuated proviral vaccine strain.
Vaccinations, as previously documented [24–28], consisted of two
inoculations of 103 TCID50 of EIAVD9 administered at a 1-month
interval (Figure 4 A–E). All subjects were monitored daily for
clinical signs of adverse reaction to the vaccine or the development
of vaccine-associated EIA. Blood samples were drawn at regular
intervals for measurement of platelets, plasma virus levels, and
EIAV-specific humoral and cellular immune responses. Attenuat-
ed vaccine viral loads appeared typical as compared to previously
published data, starting at approximately 103 copies and steadily
increasing to 104–105 copies, and averaging a steady state level of
approximately 104 copies RNA/ml plasma. The average viral load
for all vaccinates on the day of challenge was 66104 copies of
RNA/ml plasma. One vaccinate, pony #I28, experienced an
increase in rectal temperature pre-challenge, but the mild decrease
in platelets, and the lack of viremia during this episode indicate
that the fever was non-EIAV related.
Day of challenge immune responses in all vaccinates were
examined utilizing standard procedures established in multiple
pathogenesis and vaccine trials by our research group
[15,18,19,23–27,41,42,46]. Initial immunogenicity of the vaccine
strain was confirmed by reactivity testing in typical USDA-
approved commercial diagnostic assays for EIAV infection, the
USDA reference agar gel immunodiffusion (AGID) test [47] and
the ELISA-based ViraCHEKH assay [24], based on detecting
antibody to the viral capsid protein, p26. All experimentally
vaccinated horses were seropositive on the day of challenge by
these standard assays (data not shown). Quantitative and
qualitative humoral and cellular evaluations for each vaccinate
were performed next (Figure 5). Concanavalin A (ConA) ELISAs
were utilized to characterize the DOC EIAV Env-specific immune
responses of the EIAVD9 vaccinated ponies. No remarkable
differences in the endpoint titer of EIAV Env-specific IgG were
observed between vaccinates (Figure 5A). All animals developed a
pre-challenge, steady-state reciprocal titer of Env-specific antibod-
ies characteristic of a mature immune response to EIAV, ranging
between 103 and 104. The qualitative serological assay of antibody
avidity also demonstrated similar envelope-specific antibody
responses among the different vaccinates. Steady-state avidity
values of 50–70%, indicative of a mature, protective antibody
response were observed (Figure 5B). Similarly, DOC antibody
conformation ratios demonstrated values indicative of a mature
antibody response signaling a switch of antibody specificity from
predominantly linear to conformational epitopes, ranging between
0.5 and 1.0 (Figure 5C). Neutralizing antibody titers examined the
ability of DOC immune sera to inactivate both the virulent,
historical reference EIAVPV strain and the EVNTerm challenge
strain infectivity, as summarized in Figure 5D. These data
demonstrated that the EIAVD9 attenuated candidate generated
50% antibody neutralizing titers around 102, which is typical for
the EIAVD9 attenuated strain. The neutralizing antibodies of all
vaccinates inactivated both EIAVPV and EVNTerm at levels above
background, but did not distinguish between the protected from
the unprotected vaccinates. Finally, to examine the ability of the
EIAVD9 vaccine to elicit virus-specific cellular responses, Env-
specific reactivity of isolated DOC PBMC were measured in our
peptide interferon gamma (IFNc) ELISpot assay (Materials and
Methods) as summarized in Figure 5E. In general, vaccinated
ponies demonstrated equivalent Env-specific reactivity, responses
averaging between 50–75 SFC/million cells. Overall there were
no discriminating differences in humoral and cellular immune
responses in the five EIAVD9 vaccinated animals.
Clinical and Virological Profiles of Vaccinated Animals
Challenged with EVNTerm
Protective efficacy of the immune responses elicited by the
attenuated virus inoculation, and the potential of the EV0 N-
terminal gp90 sequences to confer protective efficacy to the EV13
backbone, were examined by challenging the immunized ponies
with the pathogenic EIAV chimeric strain, EVNTerm. Specifically,
six months following the second vaccine dose, the five vaccinated
ponies and a control group of four EIAV-naı¨ve ponies were
challenged with a single dose of 103 TCID50 EVNTerm. The ponies
were monitored daily for clinical symptoms of EIA, and blood
samples were drawn at regular intervals (weekly, daily if febrile) for
assays of platelets, viral replication, and virus-specific immune
Figure 1. Chimeric proviral strains replicate in vitro in equine
cells similar to parental strains. (A) Schematic illustration of the
parental EIAV strains, EV0 and EV13, and the resulting chimeric strains,
EVNTerm and EVCTerm. Boxed sites signify the variable regions (numbered
1–8) of the EIAV genome. Blue/green represents EV0-specific genome;
Yellow/pink represents EV13-specific genome; = predicted N-linked
glycosylation sites. (B) Replication kinetics of parental and chimeric
strains is plotted as RT activity (CPM/10 ml supernatant) versus days
post-infection. Infections were set up with equivalent MOIs (0.1) of
parental and chimeric viruses. Supernatants from infected FEK cells and
mock-infected cells were collected every three days and assayed for RT
activity.
doi:10.1371/journal.pone.0066093.g001
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responses. The ponies were observed for approximately 120 days
post-challenge, which was the equivalent of nearly 320 days of
observation for the entire study, at which time they were
euthanized.
As summarized in Figure 4 F–I and Figure 6, all four
unvaccinated control ponies succumbed to EIA disease by three
weeks post-challenge with EVNTerm. Increased rectal temperatures
with concurrent incidents of thrombocytopenia were observed by
16 days post-challenge (DPC) in all four animals. Disease-
associated plasma viral loads in the control group peaked between
106 and 107 copies of RNA in all four control subjects (Figure 4 F–
I). Four of the five vaccinated ponies experienced clinical EIA
during the post-challenge observation period (Figure 4 A–E,
Figure 6). One EIAVD9 vaccinate, #G28, had a fever (23 DPC)
within the expected acute stage (28 DPC) while all other
vaccinates experienced delayed-onset of disease (between 43 and
105 DPC) or no apparent disease in the case of pony #I28
(Figure 4 A–E, Figure 6). Post-challenge viral loads were higher in
the unvaccinated group as compared to the EIAVD9 vaccinated
animals. Prior to EVNTerm-associated acute disease, at 14 DPC,
the average viral load in the control group was over 10-fold higher
(46105 vs. 16104) than that of the EIAVD9 vaccinates (P = 0.0159,
Figure 7). Disease-associated viral loads in the unvaccinated group
also trended not quite 10-fold higher than those in the vaccinated
animals at acute disease averaging approximately 107 copies in the
former and 106 copies RNA/ml plasma in the latter (Figure 4, 7).
Figure 2. Clinical and virological profiles of chimeric strain pony infections. The profiles depicted in A–H display the clinical and virological
outcomes observed in EIAV chimeric strain viral infections with EVNTerm (A–D) and EVCTerm (E–H). After inoculation (0 DPI, q Infection) of EIAV-naı¨ve
ponies with 103 TCID50 I.V. injections with the respective viral strains their rectal temperatures (–, right Y axis) and platelet counts (–-, 1st left Y axis)
were followed daily for approximately 90 days (X-axis). Quantification of the plasma virus loads (X, 2nd left Y axis) on viral RNA extracted from
plasma at periodic time points were performed throughout the acute infections and during potential fever episodes of the chronic stage stages as
well. Febrile episodes are defined by achieving a combination of two-three features such as: rectal temperature above 39uC in conjunction with
thrombocytopenia (platelet decrease of $70,000/ml of whole blood), EIAV viral load $105 as well as other clinical signs of EIA. +, Animal euthanized
due to severe disease.
doi:10.1371/journal.pone.0066093.g002
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Kaplan-Meier survival curves of the protection from disease data
demonstrate a statistically significant difference between unvacci-
nated control animals and the EIAVD9 vaccinates (Figure 6).
Hence, the N-terminus of the EV0 gp90 region did not achieve
completely the high levels of protection observed previously with
EIAVD9 vaccination and challenge with EV0. However, EVNTerm
disease in the EIAVD9 vaccinated animals was significantly
delayed (P = 0.0054) as compared to unvaccinated ponies with
statistically significantly lower levels of viral levels (P = 0.015) prior
to the onset of acute disease.
Discussion
Among the diverse AIDS vaccine strategies tested to date in
animal lentivirus models, attenuated lentivirus vaccines have
uniformly provided the highest levels of immunogenicity and
protection from disease [24,30,48–58]. Important lessons on the
fundamentals of vaccine immunogen design, development, trial
approaches, and correlates of protection can be learned from
studies of this highly successful vaccine regimen. For approxi-
mately 15 years we have utilized our EIAV attenuated vaccine
platform to inform thoughtful immunogen composition of vaccines
for lentivirus diseases. We recently published a report that
established an absolute relationship between defined natural
lentivirus Env variation and vaccine efficacy. The study presented
here was designed to evaluate if the vaccine efficacy associated
with the high level of observed protection to the EV0 strain (100%)
could be conferred to the EV13 strain (40% protection) through
selected mapping of EV0 gp90 amino acid sequences.
While the generation of chimeric strains is simple in concept, it
is not always simple in practice. Both the parental strain EV0 and
EV13 Env gp90s are from viral isolates that arose from the same
experimental infection [19,42,44] during the acute and inapparent
stages of disease (EV13 evolving approximately 1200 days after
EV0) and were therefore ‘‘siblings’’ of the same biological clone,
EIAVPV. This ancestral relationship between the strains precip-
itated the anticipation of a simple swap between the N-terminal
and the C-terminal halves of the respective isolate Env gp90s with
little expectation of complications. Cloning occurred readily, and
all in vitro evidence (Figure 1B) indicated the strains had very
similar replication characteristics. In vivo infection studies with the
two strains yielded more complicated results.
The EVNTerm induced disease in three of four infected ponies,
achieving the somewhat expected level of virulence. The lack of
virulent disease in 75% of the EVCTerm animals (Figure 2, 3) was
far more unexpected. The cause of the observed lower viral
replication, which played a role in the lack of clinical disease, was
not clear. In vivo trials of the EV13 clone demonstrated a higher
level of virulence than the EV0 in pathogenicity studies prior its
use as a challenge strain (data not shown, [27]). The EVCTerm
contains the N-terminus of the gp90 of the EV13 clone, which
contains the highly variable V3–V4 genomic region that encodes
the principal neutralizing domain (PND). Furthermore, previous
studies by us and others determined that the V3–V4 region of
gp90 is an area highly associated with neutralization sensitivity or
resistance and is therefore thought to be a determinant of viral
virulence [18,42,59–62]. Thus, having the EV13 V3–V4 region in
the EVCTerm chimeric clone lead to the understandable, yet
inaccurate, theory that the chimeric provirus would be highly
virulent. However, it is likely that amino acid differences in the
reciprocal termini of the parental proviral clones compensate for
structural differences that are not accounted for in the chimeric
exchanges. The gp90 conformation is therefore potentially
compromised just enough that simple in vitro replication appears
normal yet the complications of in vivo replication yield a
moderately attenuated strain. Similar to this finding, a natural
EIAV isolate with a 14 amino acid deletion in the PND region of
the V3 was isolated, cloned, and evaluated for replication in vitro
and in vivo. The isolate, which was also predicted to be highly
pathogenic, did not cause disease in animals through a yearlong
observation period [18]. Taken together with the results of the
current pathogenicity trial, the data suggest limitations of
predicting in vivo viral virulence based on in vitro determinations
of neutralization resistance and sensitivity. More important
towards immunogen development are considerations of confor-
mational differences between strains and their respective effects on
the recognition of immune response that do not necessarily include
standard measures of 50% neutralization titers. Unfortunately,
since EIAV lacks a crystal structure for its gp90 protein,
reasonable estimates of differences in protein structure are not
possible here. The outcome of the pathogenicity trial precluded
the use of the EVCTerm as a challenge strain for assessment of
protection from disease. While the reciprocal gp90 exchange in the
EVCTerm strain would have been ideal, the lack of virulence in the
EVCTerm strain would have made challenge results impossible to
interpret. Therefore, the EIAVD9 vaccine trial commenced with a
single chimeric challenge strain.
EIAVD9 vaccination yielded a statistically significantly lower
level of post-challenge EVNTerm viral levels and delay in clinical
EIA disease (Figure 6, 7). This delay in disease was also a longer
delay than the typical time to disease noted in challenge studies
with the parental EV13 [27]. However, four of five animals still
developed clinical EIA, unlike the high levels of protection
observed with EV0 parental strain in the previous study. Based
on the virulence and neutralization sensitivity associated with the
V3–V4 epitopes, it was expected that the chimeric EVNTerm strain
(EV0 N-terminus), which is homologous in the N-terminal region
to the EIAVD9 vaccine, would have increased protective efficacy
compared to the EV13 parental strain. Moreover, the assumption
that protective antibodies would be generated to the PND region
by the vaccine strain, in light of the 100% homology between the
EIAVD9 and EVNTerm in the V3–V4 region, prejudiced expecta-
tions of higher levels of protection. Neither protective nor virulent
Env epitopes have been mapped to the C-terminus of the gp90
Figure 3. Chimeric strain infections did not result consistently
in clinical disease. The percentage of animals within each trial group,
EVNTerm and EVCTerm that did not develop clinical EIA was plotted as a
function of days post-infection.
doi:10.1371/journal.pone.0066093.g003
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protein. An earlier report did note a neutralization domain in the
V5 region [63], but subsequent studies on regional epitope
conferment of neutralization sensitivity and resistance yielded no
indications of consequence in the C-terminus. The most notable
change within the 26 amino acid differences between the EIAVD9
C-terminus and the EV13/EVNTerm C-terminus was the reduction
in the number of potential N-linked glycosylation sites (four fewer
sites, Figure 1A). This reduction in glycosylation typically would be
Figure 4. Clinical and virological profiles of EVNTerm challenged vaccinated and naı¨ve ponies. The profiles depicted in A–I display the
clinical and virological outcomes observed in EIAVD9 vaccinated animals (A–E), and EIAV naı¨ve animals (F–I) upon challenge with 10
3 TCID50 EVNTerm
chimeric proviral strain. (A–E) Five EIAV-naı¨ve ponies were vaccinated with 103 TCID50 EIAVD9 I.V. (q Vax q). Rectal temperature (–, right Y axis) and
platelet counts (–-, first left Y axis) were followed daily for up to 300 days (X-axis) after the first vaccine dose. Quantification of the virus load (X,
second left Y axis) was performed on viral RNA extracted from plasma at periodic time points prior to and after virulent virus challenge seven months
post-first vaccination with 103 TCID50 EVNTerm, I.V. (qChallenge). (F–I) Four EIAV-naı¨ve ponies were also challenged with 10
3 TCID50 EVNTerm, I.V.
(qChallenge). Febrile episodes were defined by a achieving a combination of two-three features such as: rectal temperature above 39uC in
conjunction with thrombocytopenia (platelet decrease of $70,000/ml of whole blood), EIAV viral load $105 as well as other clinical signs of EIA.
doi:10.1371/journal.pone.0066093.g004
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Figure 5. Day of challenge humoral and cellular immune responses of EIAVD9 vaccinates. Characterization of the quantitative and
qualitative properties of induced EIAV envelope-specific humoral and cellular responses on the day of challenge were conducted in ConA serological
ELISA assays of serum antibody (A) endpoint titer, (B) avidity, and (C) conformational dependence; (D) 50% serum neutralization titer determinations,
and (E) INF-c ELISpot of PBMC, all as described in Materials and Methods. (A) Mean serum antibody titers are presented as the log10 of the highest
reciprocal dilution yielding reactivity two standard deviations above background. (B) Mean avidity index measurements are presented as percentages
of the antibody-antigen complexes resistant to disruption with 8 M urea. (C) Mean conformation dependence values are calculated as the ratio of
serum antibody reactivity with native envelope compared to denatured envelope antigen. Conformation ratios greater than 1.0 indicate predominant
antibody specificity for conformational determinants, while ratios less than 1.0 indicate predominant antibody specificity for linear envelope
determinants. (D) The mean reciprocal dilutions of serum from vaccinated horses which neutralized 50% of input EIAVPV or EVNTerm, as measured in
an infectious center assay. The line (–-) denotes the cut off ($25) value for valid 50% neutralization titers. (E) EIAV Env-specific cellular activity
measured as the mean INF-c ELISpot analysis of EIAV gp90 peptide stimulation of PBMC from vaccinated horses. SFC, Spot-forming Cells.
doi:10.1371/journal.pone.0066093.g005
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predicted to render the region more vulnerable to neutralization
and hence, less pathogenic. It is possible that sensitivity to
neutralization, with a less dense glycosylation shield, is what
allowed for delay in disease. In light of previous findings of
immune escape and the evolution of EIAV with each febrile
episode [19,42,44], it is highly likely that the isolates that escaped
vaccine immunity evolved from the infectious inoculum given the
amount of time between challenge and disease in many of the
vaccinates. Recognizing the effects that glycosylation has on
protein structure [64,65], it is also very probable that the
differences in glycosylation cause subtle differences in the EVNTerm
structural conformation of the gp90 protein which allows escape of
the EIAVD9–induced protective immunity.
Examination of the day of challenge immune response did not
reveal any apparent correlates of protection. Env-specific serolog-
ical analyses were indicative of a mature protective immune
response as demonstrated previously [25–27]. The IFNc ELISpot
assay of cellular reactivity is new to our studies and has no
historical reference, but results while indicative of Env-specific
responses did not distinguish between the single protected
vaccinate and the other four unprotected vaccinates. One point
that could be made regarding the Env-specific serological results
was the moderately low conformation ratio for pony #G28. Most
vaccinated animals display DOC antibody conformation ratios
higher than 0.5 and are closer to 1.0, indicative of an increase in
recognition of predominantly conformational epitopes instead of
linear epitopes. This relatively low antibody conformation
dependence may potentially explain why pony #G28 is the only
vaccinate to break with acute disease within the normal timeframe.
All vaccinated animals had neutralization titers to EIAVPV and
EVNTerm. The 50% neutralizing antibody titers were typical of
EIAV-specific immunity but did not distinguish between the
protected vaccinate and the other four unprotected vaccinates.
While antibody responses clearly play a key role in EIAV vaccine
efficacy, results presented here support a platform that adopts
refocusing of assays to find correlates of key, non-neutralizing
antibody measures, as suggested by the findings of the well
reported HIV RV144 vaccine trial. Specifically the finding of V1–
V2 binding antibodies, not neutralizing antibodies, as a correlate
of protection share a similar theme with the findings observed in
the current trial [66–68].
The data presented in this report demonstrate some interesting
observations of in vitro mapping of in vivo interactions with
lentiviral proteins. The pathogenicity trial of the chimeric EIAV
Figure 6. EVNTerm chimeric viral strain clinical disease is
significantly different than disease in unvaccinated controls.
The percentage of EIAVD9 vaccinated and unvaccinated control animals
that were protected from clinical EIA upon challenge with EVNTerm were
plotted as a function of days post-infection. Kaplan-Meier survival plots
were generated plotting protection from disease as ‘‘0’’ at the end of
the study (120 days post challenge) and disease as ‘‘1’’ on the first day
of disease in GraphPad Prism 6.0a (GraphPad Software Inc., LaJolla, Ca.).
Gehan-Breslow-Wilcoxon test for statistical relevance demonstrated a
significant difference in the survival curves, P = 0.0054.
doi:10.1371/journal.pone.0066093.g006
Figure 7. Viral loads in vaccinated ponies and naı¨ve ponies present distinguishing differences. The longitudinal average of the viral
loads, quantitated from plasma RNA, for the challenged vaccinates as well as the challenged unvaccinated ponies were plotted as a function of the
observation period (approximately 300 days). Red symbols in both groups indicate a single animal’s viral level during febrile episode. DOC, Day of
challenge; *, Mann-Whitney statistical results, P = 0.015.
doi:10.1371/journal.pone.0066093.g007
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strains demonstrated that reciprocal swaps between variant Env
species of virulent isolates do not always yield a virulent virus.
Furthermore, the current observations indicate that in vitro assays
of regional epitope determinants of neutralization sensitivity and
resistance do not necessarily reveal in vivo epitopes of virulence.
Vaccine efficacy studies demonstrated that homology between the
N-terminus of the vaccine and challenge strain gp90s was capable
of inducing immunity that resulted in significantly lower levels of
post-challenge virus and significantly delayed the onset of EIA
disease. However, a homologous N-terminal region alone could
not impart complete protection. Both the pathogenicity and
vaccine efficacy studies suggest that large regional residue
exchanges potentially affect conformation by excluding compen-
satory mutations. Smaller sequence swaps are less likely to have
large-scale conformational effects that could alter the virulence of
the strains. These studies ultimately emphasize the importance of
focusing vaccine efforts on structural accuracy and conformational
integrity of Env immunogens. Furthermore, future studies should
aim on engineering new assays of antibody binding that distinguish
correlates of protection that inform development of novel Env
immunogens that elicit a broader and more effective recognition of
variant Env species.
Materials and Methods
Design, Construction, and Production of Chimeric EIAV
virus Strains
Chimeric EIAV proviral strains were produced from the viral
challenge strains developed for a previous study on variant
envelope effects on vaccine efficacy [27,28]. Two chimeric proviral
EIAV strains were created utilizing the virulent EV0 and EV13
EIAV strains [27] (gp90 envelope sequences: GenBank accession
numbers AF016316.1, and AY858747.1, respectively). Proviral
strains EVNTerm and EVCTerm (Figure 1) were generated utilizing a
combination of PCR-generated fragments and standard restriction
endonuclease digestions to create chimeric proviral strains from
the N-terminus and C-terminus of both EV0 and EV13, splitting
and recombining the strains between the fourth and fifth variable
regions (Figure 1). Standard PCR conditions were employed
[18,27]. The resultant PCR products of the desired envelope
fragments were gel purified, digested, and cloned back into the
backbone of the respective counterpart EIAV strains [27]. All
proviral clones were sequenced to verify the swapped envelope
sequences. Sequencing reactions were performed with the Taq
Dye Deoxy Terminator Cycle Sequencer Kit (Applied Biosystems,
Foster City, CA) using internal EIAV primers [19,42,44]. DNA
sequences were resolved with an ABI Prism 373 DNA sequencer
(Applied Biosystems, Foster City, CA). Viral stocks were prepared
by harvesting the supernatant medium from equine dermal (ED)
cells (ATCC CRL 6288) as preciously described [69]. Viral stock
titers were determined utilizing our infectious center assay (cell-
based ELISA) in FEK cells, described previously [70,71]. In vitro
viral replication kinetics of the chimeric strains was determined as
previously described by reverse transcriptase (RT) activity analysis
of supernatants from infected FEK cells [43,69,72].
Experimental Subjects, Inoculations, Clinical Evaluation,
and Sample Collection
All equine procedures were conducted in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health at the
Gluck Equine Research Center of the University of Kentucky
according to protocols approved by the University of Kentucky
IACUC (#01058A2006). The animals were monitored daily and
maintained as described previously [25–27,40,42]. Platelet num-
bers were determined using the IDEXX VetAutoread Hematology
Analyzer (IDEXX Laboratories Inc., Westbrook ME). Clinical
EIA (fever) episodes were determined on the basis of rectal
temperature and platelet count (rectal temperature .39uC;
platelet number ,100,000/ml of whole blood) in combination
with the viremic presence of infectious plasma virus (.105)
[13,16,40,42,73]. Samples of whole blood, serum, and plasma
were collected weekly as well as daily during fever episodes.
Plasma samples were stored at 280uC until used to determine
plasma viral RNA level. Serum samples for serological analysis
were stored at 220uC. Peripheral blood mononuclear cells
(PBMC) were isolated using Ficol-Paque PlusTM (Amersham
Biosciences, Piscataway, NJ) gradient centrifugation. PBMC were
cryopreserved and stored in liquid nitrogen for ELISpot analysis of
INFc production. During the course of these experiments ponies
that demonstrated severe disease-associated symptoms resulting in
distress as outlined by the University of Kentucky IACUC were
euthanized.
Experimental infections to determine virulence. Eight
outbred, mixed-breed ponies were separated into two groups of
four and experimentally inoculated intravenously with 103
TCID50 of either chimeric strain EVNTerm and EVCTerm. Rectal
temperatures and clinical status were recorded daily. The ponies
were monitored for clinical, virological, and immune responses as
described above.
Attenuated vaccine inoculations and challenge. Eight
outbred, mixed-breed ponies of mixed age and gender and
serognegative for EIAV were utilized. Daily rectal temperatures
and clinical status were recorded. The EIAVD9 attenuated virus
stock was produced and vaccinations performed as described [25–
27]. Five ponies were vaccinated and four were maintained as
EIAV-naı¨ve, unvaccinated control animals. All vaccinated ponies
received two inoculations of EIAVD9 at 1-month intervals by
intravenous injection of 103 TCID50 as previously described
[26,27]. Vaccinated ponies were challenged six months post-
second inoculation with 103 TCID50 EVNTerm. Unvaccinated
controls were challenged at the same time as their vaccinated
counterparts. Ponies were monitored daily for clinical symptoms of
EIA. Virological and immunological responses were monitored as
described above and in the following sections.
Viral RNA Purification and Quantitation
Circulating plasma viral load analysis of all animals was
analyzed using a previously described Taqman quantitative real-
time multiplex RT-PCR assay based on gag-specific amplification
primers [74]. The standard RNA curve of the assay was linear
within the range of 101 molecules as a lower limit and 108
molecules as an upper limit. Statistical significance of the
differences in the average viral loads in challenged vaccinated
animals versus naı¨ve animals was determined using a nonpara-
metric, Mann-Whitney test (Prism 6.0a, GraphPad Software, Inc.,
La Jolla, CA).
Quantitative and Qualitative Serological Analyses
Detection of serum antibody reactivity to the EIAV capsid
protein p26 was conducted using the ViraCHEKH/EIA kit per the
manufacturer’s instructions (Synbiotics Laboratory, Via Frontera,
San Diego, CA). Serum samples were also evaluated for
seroreactivity by the standard agar gel immunodiffusion (AGID)
procedure [47] diagnostic assay for EIA. Serum IgG antibody
reactivity to EIAV envelope glycoproteins was assayed quantita-
tively (end point titer) and qualitatively (avidity index, conforma-
tion ratio) using our standard ConA ELISA procedures as
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described previously [15,41,75]. Virus neutralizing activity to
EIAVPV (historical reference and homologous to vaccine Env) as
well as the EVNTerm challenge virus strain mediated by immune
sera was assessed in an indirect cell-ELISA based infectious center
assay using a constant amount of infectious virus (50 units) and
sequential 2-fold dilutions of serum [41,71]. All serological
analyses experiments were performed in triplicate.
INFc ELISpot Analysis of PBMC
MultiScreenHTS-IP Filter plates (Millipore, Bedford, MA) were
coated with 7.5 mg/ml monoclonal mouse-anti bovine IFNc
antibody at room temperature for four hours. Plates were washed
with PBS and blocked for one hour with RPMI media (2.5% fetal
equine serum, 2 mM glutamine, 100 U/ml penicillin/streptomy-
cin, and 55 mM 2-mercaptoethanol). Cryopreserved PBMC were
thawed and 26105 cells added to triplicate wells. Env gp90
peptides [27,33,34] were added at a final concentration of 20 mg/
ml. Medium only (negative) controls did not contain peptides.
Phytohemaglutinin (PHA, 10 mg/ml) was used as positive control.
Plates were incubated at 37uC/5% CO2 for 16 hours. Plates were
washed with PBS and biotinylated mouse-anti bovine IFNc
antibody (diluted in PBS/0.5% FBS) added to each well at the
final concentration of 0.25 mg/ml. After incubation for two hours
at 37uC, plates were washed with PBS. Streptavidin-alkaline
phosphatase (Mabtech, Mariemont, OH) was added and the plates
incubated for one hour. Spots were developed by incubating the
plates with substrate BCIP-NBTPLUS (Mabtech, Mariemont,
OH) for 30 min and stopped by rinsing with distilled water. Spots
were scanned and analyzed on an Immunospot Analyzer (Cellular
Technology, Cleveland, OH). The number of IFNc producing
cells were calculated as mean values of triplicate wells, minus
background medium controls, and shown as spot forming cells
(SFC per million PBMC).
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